Shots:

• Lexeo acquires exclusive rights to three preclinical AAV-mediated gene therapy programs for the treatment of rare cardiac disorders- focused on TNNI3-associated HCM & ARVC
• The acquisition will complement and bolster LEXEO’s advanced pre-clinical gene therapy pipeline with the addition of three novel programs for rare cardiac diseases
• Additionally- preclinical results from the TNNI3-associated HCM gene therapy program showed compelling expression of the human TNNI3 gene in the heart in mouse models & two ARVC gene therapy programs demonstrated delivery of the gene that codes for Cx43 & PKP2

| Ref: Globe Newswire | Image: Yahoo Finance